Autopsy report · NCT05330208

Single Ascending Dose and Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-1816 in Healthy Subjects

“Sponsor internal strategy change.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 4 months before it stopped.
• 60 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Beijing Suncadia Pharmaceuticals Co., Ltd

Sponsor type

Industry

Conditions

Diabetes

Interventions

SHR-1816; Placebo

Participants

60

Sites

1

Countries

China

Trials that died the same way

• Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients
  “sponsor strategy change” (89% match in meaning)
• POWER Study (Prospective Transbronchial Microwave + Robotic-Assisted Bronchoscopy)
  “Change in Sponsor strategy” (85% match in meaning)
• Effects of Dietary Supplements on Nail and Hair Health
  “Strategic change by sponsor” (85% match in meaning)
• Safety and Efficacy of Gaseous Nitric Oxide on Venous Stasis Leg Ulcers
  “Strategic direction of the sponsor changed” (81% match in meaning)
• Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy
  “Sponsor change” (78% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.